Damage and deleterious effects of the Great East Japan Earthquake
| Ulcerative colitis (N=546) | Crohn's disease (N=357) | Total (N=903) | |
|---|---|---|---|
| Damage to houses | |||
| Total loss (≥50%) | 36 (6.6%) | 38 (10.6%) | 74 (8.2%) |
| Half-loss (≥20% but <50%) | 37 (6.8%) | 21 (5.9%) | 58 (6.4%) |
| Partial loss (≥3% but <20%) | 236 (43.2%) | 133 (37.3%) | 369 (40.9%) |
| None | 233 (42.7%) | 161 (45.1%) | 394 (43.6%) |
| Unclear | 4 (0.7%) | 4 (1.1%) | 8 (0.9%) |
| Temporary homelessness | |||
| 1 week or more | 37 (6.8%) | 25 (7.0%) | 62 (6.9%) |
| Less than 1 week or none | 503 (92.1%) | 331 (92.7%) | 834 (92.3%) |
| Unclear | 6 (1.1%) | 1 (0.3%) | 7 (0.8%) |
| Death of family members or friends | |||
| Yes | 106 (19.4%) | 69 (19.3%) | 175 (19.4%) |
| None | 435 (79.7%) | 284 (79.6%) | 719 (79.6%) |
| Unclear | 5 (0.9%) | 4 (1.1%) | 9 (1.0%) |
| Changes in daily dietary intake | |||
| Yes | 153 (28.0%) | 116 (32.5%) | 269 (29.8%) |
| No | 387 (70.9%) | 239 (66.9%) | 626 (69.3%) |
| Unclear | 6 (1.1%) | 2 (0.6%) | 8 (0.9%) |
| Discontinuation of medications | |||
| 1 week or more | 39 (9.8%) | 30 (14.1%) | 69 (11.7%) |
| None | 507 (9.8%) | 327 (14.1%) | 834 (11.7%) |
| Unclear | 358 (90.2%) | 256 (85.9%) | 614 (88.3%) |
| Interruption in IFX or ADA | |||
| Yes | 1/18 | 19/162 | 20/180 |
| Complete loss of job | |||
| Yes | 26 (4.8%) | 25 (7.0%) | 51 (5.7%) |
| None | 518 (94.9%) | 330 (92.4%) | 848 (93.9%) |
| Unclear | 2 (0.3%) | 2 (5.6%) | 4 (0.4%) |
| Anxiety about family finances | |||
| Yes | 167 (30.6%) | 145 (40.6%) | 312 (34.6%) |
| (Short-term anxiety) | (147) | (132) | (279) |
| (Long-term anxiety) | (83) | (74) | (157) |
| None | 376 (68.9%) | 211 (59.1%) | 587 (65.0%) |
| Unclear | 3 (0.5%) | 1 (0.3%) | 4 (0.4%) |
| Changes in smoking status | |||
| Stopped after the earthquake | 9 | 5 | 14 |
| Restarted after the earthquake | 10 | 5 | 15 |
Short-term anxiety indicates anxiety about their family finances for the next several months. Long-term anxiety indicates anxiety about their family finances for the next several years or more.
ADA, adalimumab; IFX, infliximab.